Drugs / MK-6552
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06567002 | Sep → Nov 2024 | — | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT06662396 | Jun → Sep 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06619665 | Mar → Jul 2024 | narcolepsy | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06179407 | Jan → Oct 2024 | narcolepsy | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT06665230 | Sep → Nov 2023 | narcolepsy | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-6552 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06567002 ↗ |
| Route | Oral | “Oral capsule” NCT06179407 ↗ |